← All trials
NCT01627223
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2012
- Primary completion
- Apr 1, 2016
- Completion date
- Apr 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 17
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Taichung Veterans General HospitalLead sponsor
- Chiayi Christian HospitalOverall official - principal investigator
- Taichung Veterans General HospitalOverall official - principal investigator
- Changhua Christian HospitalOverall official - principal investigator
- Chung Shan Medical UniversityOverall official - principal investigator
- ChengChing HospitalOverall official - principal investigator
- National Taiwan UniversityOverall official - principal investigator
- Tung's Taiching MetroHarbor HospitalOverall official - principal investigator
- GlaxoSmithKlineCollaborator
- Taichung Veterans General HospitalReponsible party - principal investigator
- China Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.